Literature DB >> 1665959

Potentiating effect of ribavirin on the anti-herpes activity of acyclovir.

S N Pancheva1.   

Abstract

The combined antiviral effects of acyclovir (ACV) and ribavirin (Rbv) on herpes simplex virus type 1 (HSV-1) and pseudorabies virus (PRV) in cell cultures and on experimental HSV-1 keratitis in rabbits were studied. The antiviral activity in vitro was based on cytopathogenicity inhibition and yield reduction. The combination of the two drugs exhibited synergy as evaluated graphically (isobolograms). Rbv also potentiated the antiviral effect of ACV in vivo, in the experimental HSV-1 keratitis model in rabbits. This was evident from both the severity of corneal lesions and virus shedding in the tear film. The potentiating effect of Rbv on the anti-HSV-1 activity of ACV in vitro was reversed by guanosine.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1665959     DOI： 10.1016/0166-3542(91)90021-i

Source DB:  PubMed          Journal:  Antiviral Res        ISSN： 0166-3542            Impact factor:   5.970


  9 in total

1.  Controversies' clarification regarding ribavirin efficacy in measles and coronaviruses: Comprehensive therapeutic approach strictly tailored to COVID-19 disease stages.

Authors:  George D Liatsos
Journal:  World J Clin Cases       Date:  2021-07-06       Impact factor: 1.337

Review 2.  Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  A J Wagstaff; D Faulds; K L Goa
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

Review 3.  Mechanisms of action of ribavirin against distinct viruses.

Authors:  Jason D Graci; Craig E Cameron
Journal:  Rev Med Virol       Date:  2006 Jan-Feb       Impact factor: 6.989

Review 4.  Inhibitors of Nucleotide Biosynthesis as Candidates for a Wide Spectrum of Antiviral Chemotherapy.

Authors:  Claudia Soledad Sepúlveda; Cybele Carina García; Elsa Beatriz Damonte
Journal:  Microorganisms       Date:  2022-08-12

5.  Substituted imidazopyridines as potent inhibitors of HCV replication.

Authors:  Inge Vliegen; Jan Paeshuyse; Tine De Burghgraeve; Laura S Lehman; Matthew Paulson; I-Hung Shih; Eric Mabery; Nina Boddeker; Erik De Clercq; Hans Reiser; David Oare; William A Lee; Weidong Zhong; Steven Bondy; Gerhard Pürstinger; Johan Neyts
Journal:  J Hepatol       Date:  2009-02-26       Impact factor: 25.083

Review 6.  Current Status and Challenge of Pseudorabies Virus Infection in China.

Authors:  Lei Tan; Jun Yao; Yadi Yang; Wei Luo; Xiaomin Yuan; Lingchen Yang; Aibing Wang
Journal:  Virol Sin       Date:  2021-02-22       Impact factor: 4.327

7.  Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections.

Authors:  Robert O Baker; Mike Bray; John W Huggins
Journal:  Antiviral Res       Date:  2003-01       Impact factor: 10.103

8.  Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.

Authors:  Lotte Coelmont; Suzanne Kaptein; Jan Paeshuyse; Inge Vliegen; Jean-Maurice Dumont; Grégoire Vuagniaux; Johan Neyts
Journal:  Antimicrob Agents Chemother       Date:  2008-12-22       Impact factor: 5.191

9.  Potential Virus Involvement in Alzheimer's Disease: Results from a Phase IIa Trial Evaluating Apovir, an Antiviral Drug Combination.

Authors:  Nina Lindblom; Lars Lindquist; Jacob Westman; Mikael Åström; Roger Bullock; Suzanne Hendrix; Lars-Olof Wahlund
Journal:  J Alzheimers Dis Rep       Date:  2021-05-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.